• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • NMPA Strengthens Supervision of Medical Devices for China Procurement

NMPA Strengthens Supervision of Medical Devices for China Procurement

Monday, 25 October 2021 / Published in Medical Device, News, NMPA Registration in China

NMPA Strengthens Supervision of Medical Devices for China Procurement

On September 18, 2021, the NMPA (National Medical Products Administration) announced the implementation of a work plan for strengthening the supervision of medical devices selected for centralized procurement in China as an effective measure to ensure product quality and safety.

The NMPA and the provincial MPAs will further effectively enhance their supervision work in future by taking the initiative to collect the information of the suppliers in time. Through the full implementation of the main responsibility of the suppliers for quality and safety and through the enhancement of the supervision responsibility of the regulatory departments, the NMPA intends to achieve a full-coverage inspection and a full-coverage sampling to effectively guarantee the quality and safety of the selected medical devices in the centralized procurement with quantity. 

Highlights

The work plan focused on:

  • The responsibility of the suppliers.
    • Report promptly to the local provincial MPA (medical products administration). The registration agent of imported medical devices shall also report the selection status to the local MPA timely.
    • Strengthen quality management. In accordance with the requirements of medical device laws and regulations and the provisions for production quality management, the manufacturers shall continue to improve the quality management system, improve the quality management level, strengthen raw material audit and supplier management, carefully investigate hidden risks in the production process, and effectively strengthen the quality control of the production process. The companies shall also take effective measures to ensure that product quality meets the mandatory standards and the technical requirements of registered product.
    • Strictly carry out adverse event monitoring. The manufacturers shall implement relevant regulatory requirements for adverse events, strengthen the collection, reporting, analysis and handling of adverse events, and strengthen the life-cycle risk management of selected products.
    • Establish a sound tracing system. In accordance with the requirements for the implementation of the unique identification of medical devices, the companies shall carry out product code assignment, data upload and maintenance, establish and improve the tracing system based on the unique identification, and do a good job in product recall, product trace and other related work.
  • Effectively strengthen the supervision and management of the selected enterprises.
    • Strengthen the daily supervision of the selected enterprises and realize the management of “One company, one file”.
    • Strengthen the supervision and inspection of the selected enterprises, and achieve full-coverage inspection every year (unannounced inspection).
    • Supervise the selected companies on a quarterly basis, require each company to report the system operation and product quality status.
    • Organize and carry out special trainings on a regular basis with the company’s responsible person, management representatives, etc., and assess their understanding on the latest laws and regulations, product standards, and regulatory requirements for medical devices. The assessment results will be registered in the corporate credit file.

By Judith Sun. Contact Cisema if you would like to learn more.

Tagged under: china procurement

What you can read next

china cosmetics label requirements
China Cosmetics Label Requirements for Ingredients added to Cosmetic Raw Materials
Some Medical Devices Exempted from Clinical Trials
NMPA Solicits Public Opinions on the Reclassification of IVD Reagents

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP